Skip to main content

Advertisement

SpringerLink
Log in

Long-term use of basal insulin and the risk of breast cancer

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wu JW, Azoulay L, Majdan A, Boivin JF, Pollak M, Suissa S (2017) Long-term use of long-acting insulin analogs and breast cancer incidence in women with type 2 diabetes. J Clin Oncol. https://doi.org/10.1200/JCO.2017.73.4491

    PubMed Central  Google Scholar 

  2. Ogdie A, Langan S, Parkinson J, Dattani H, Kostev K, Gelfand JM (2012) Medical record databases. In: Strom BL, Kimmel S, Hennessy S (eds) Pharmacoepidemiology, 5th edn. University of Pennsylvania, Philadelphia, pp 224–243

    Chapter  Google Scholar 

  3. Kostev K (2012) Risk of breast cancer in patients on insulin glargine and insulin detemir in comparison with those on human insulin. Diabetologia 55(5):1554–1555

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Philipps-University Marburg, Marburg, Germany

    Karel Kostev & Matthias Kalder

  2. Epidemiology, IQVIA, Frankfurt, Germany

    Karel Kostev

Authors
  1. Karel Kostev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Kalder
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karel Kostev.

Ethics declarations

Conflicts of interest

Karel Kostev declares that he has no conflict of interest. Matthias Kalder declares that he has no conflict of interest.

Research involving human participants

German law allows the use of anonymous electronic medical records for research purposes under certain conditions. According to this legislation, it is not necessary to obtain informed consent from patients or approval from a medical ethics committee for this type of observational study that contains no directly identifiable data.

Informed consent

Because patients were only queried as aggregates and no protected health information was available for queries, no IRB approval was required for the use of this database or the completion of this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kostev, K., Kalder, M. Long-term use of basal insulin and the risk of breast cancer. Breast Cancer Res Treat 168, 763–764 (2018). https://doi.org/10.1007/s10549-017-4631-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4631-8

Search

Navigation